Altimmune ALT EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Altimmune’s reported figures.
The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Altimmune's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Altimmune's EBITDA?
- Altimmune (ALT) reported EBITDA of -$24.22M in Q1 2026.
- How has Altimmune's EBITDA changed year-over-year?
- Altimmune's EBITDA decreased by 11.2% year-over-year, from -$21.79M to -$24.22M.
- What is the long-term trend for Altimmune's EBITDA?
- Over 4 years (2021 to 2025), Altimmune's EBITDA has grown at a -0.5% compound annual growth rate (CAGR), from -$96.36M to -$94.38M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.